Astrazeneca Pharma India Ltd - Stock Valuation and Financial Performance

BSE: 506820 | NSE: ASTRAZEN | Pharmaceuticals & Drugs | Small Cap

Astrazeneca Pharma I Share Price

6,496.85 -9.00 -0.14%
as on 20-Dec'24 16:59

DeciZen - make an informed investing decision on Astrazeneca Pharma I

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Astrazeneca Pharma India stock performance -

mw4me loader
P/E Ratio (SA):
198.27
Market Cap:
16,242.1 Cr.
52-wk low:
4,050.2
52-wk high:
8,139.9

Is Astrazeneca Pharma India Ltd an attractive stock to invest in?

1. Is Astrazeneca Pharma India Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Astrazeneca Pharma India Ltd is a good quality company.

2. Is Astrazeneca Pharma India Ltd undervalued or overvalued?

The key valuation ratios of Astrazeneca Pharma India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Astrazeneca Pharma India Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Astrazeneca Pharma India Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Astrazeneca Pharma I:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Astrazeneca Pharma India Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % -12.9%3.8%18.7%18.7%26.5%34.6%31.2%17.4%24.5%33.9%-
Value Creation
Index
-1.9-0.70.30.30.91.61.30.30.81.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 5175645445717288328148061,0031,2961,485
Sales YoY Gr.-9%-3.6%5%27.6%14.2%-2.2%-1%24.5%29.2%-
Adj EPS -8.42.25.910.521.628.936.923.950.260.132.8
YoY Gr.-NA171.6%76.5%106.5%34.1%27.4%-35.2%110.1%19.8%-
BVPS (₹) 60.362.488.597.9119.5145.1181.8203.8234.5283.5271.7
Adj Net
Profit
-215.514.826.15472.392.259.712615082
Cash Flow from Ops. -45.75738.18.85587.410510158.327.9-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 10.7%12.2%16.8%29.2%
Adj EPS NA22.8%17.7%19.8%
BVPS18.8%18.9%16%20.9%
Share Price 23.2% 18.4% 29% 21.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
-133.67.811.119.721.722.512.322.823.111.8
Op. Profit
Mgn %
-2.636.98.29.814.616.710.716.514.310.4
Net Profit
Mgn %
-4.112.74.67.48.711.37.412.511.65.5
Debt to
Equity
00000000000
Working Cap
Days
173167185216176167193200185179114
Cash Conv.
Cycle
111711120-2-1642366

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 16.78%

Net Profit is growing at healthy rate in last 3 years 17.73%

Sales growth is good in last 4 quarters at 29.83%

Return on Equity has declined versus last 3 years average to 11.80%

Latest Financials - Astrazeneca Pharma India Ltd.

Standalone Consolidated
TTM EPS (₹) 32.8 -
TTM Sales (₹ Cr.) 1,485 -
BVPS (₹.) 271.7 -
Reserves (₹ Cr.) 730 -
P/BV 23.91 -
PE 198.27 -
From the Market
52 Week Low / High (₹) 4050.15 / 8139.85
All Time Low / High (₹) 9.00 / 8139.85
Market Cap (₹ Cr.) 16,242
Equity (₹ Cr.) 5
Face Value (₹) 2
Industry PE 44.3

Management X-Ray of Astrazeneca Pharma I:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Astrazeneca Pharma I

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales5175645445717288328148061,0031,296
Operating Expenses 5315475075256577116787198381,111
Manufacturing Costs26334459584957658294
Material Costs194195171178227300287305355590
Employee Cost 160169162150197217220230259241
Other Costs 150150129137175146115119142185
Operating Profit -141637467112113586165184
Operating Profit Margin (%) -2.6%2.9%6.8%8.1%9.8%14.5%16.7%10.7%16.5%14.2%
Other Income 871412161313152635
Interest 0000011111
Depreciation 15171615151920171615
Exceptional Items 00000000-4016
Profit Before Tax -21636447311412783134220
Tax 011518184234213558
Profit After Tax -21520265472936299162
PAT Margin (%) -4.0%0.9%3.7%4.5%7.5%8.7%11.5%7.6%9.9%12.5%
Adjusted EPS (₹)-8.32.18.010.421.828.937.324.639.764.6
Dividend Payout Ratio (%)0%0%0%0%0%3%5%41%40%37%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 151156221245299363455509586709
Share Capital 5555555555
Reserves 146151216240294358450504581704
Minority Interest0000000000
Debt0000000000
Long Term Debt0000000000
Short Term Debt0000000000
Trade Payables1119588127168210178190228197
Others Liabilities 150178205203124203241277328372
Total Liabilities 4124295145755917768749771,1421,277

Fixed Assets

Gross Block191204103106120133160169179187
Accumulated Depreciation90106163045617994110120
Net Fixed Assets101978775757281746967
CWIP 126547244210
Investments 0000000000
Inventories867758113118165160140190228
Trade Receivables4383435580838586108153
Cash Equivalents 2577116126173253352448500506
Others Assets14489206203138179192226274323
Total Assets 4124295145755917768749771,1421,277

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity -465738955871051015828
PBT -21636447311412783134220
Adjustment 9121538101410-5-7
Changes in Working Capital -3342-0-3410-3-433-30-128
Tax Paid -1-3-12-4-35-34-33-25-41-56
Cash Flow From Investing Activity -19-40-94-17117351822
Capex -24-9-5-6-18-14-5-6-5-10
Net Investments 000-1112-169169000
Others 556811129112332
Cash Flow From Financing Activity 0-1000-6-9-9-24-44
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 00000-1-1-1-1-1
Dividend Paid 00000-3-5-5-20-40
Others 00000-3-3-4-4-4
Net Cash Flow -645338-159-9026996525
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)-12.933.4310.6311.1220.0321.8322.8312.7818.1324.95
ROCE (%)-12.933.7618.7418.6526.5334.6131.2417.3624.4933.94
Asset Turnover Ratio1.271.361.161.051.251.220.990.870.951.08
PAT to CFO Conversion(x)N/A11.41.90.351.021.211.131.630.590.17
Working Capital Days
Receivable Days33404231343638393537
Inventory Days63524555586273686059
Payable Days208193194220238230247220215131

Astrazeneca Pharma India Ltd Stock News

Astrazeneca Pharma India Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Astrazeneca Pharma I on 20-Dec-2024 16:59 is ₹6,496.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Astrazeneca Pharma I stood at ₹16,242.1.
The latest P/E ratio of Astrazeneca Pharma I as of 20-Dec-2024 16:59 is 198.3.
The latest P/B ratio of Astrazeneca Pharma I as of 20-Dec-2024 16:59 is 23.91.
The 52-week high of Astrazeneca Pharma I is ₹8,139.9 and the 52-week low is ₹4,050.2.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Astrazeneca Pharma I is ₹1,485 ( Cr.) .

About Astrazeneca Pharma India Ltd

Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.

The company’s Global Technology Centre (GTC) in Chennai, is its primary insourced IT facility delivering significant value to the business through an end-to-end, integrated IT service delivery mode. The centre was set up in September 2014 in Chennai, Tamil Nadu, India with the mandate to deliver best in class IT service for the global business.

The company launched its R&D Bangalore in 2017 to support AstraZeneca’s global established medicines portfolio. The R&D Bangalore team provides support across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases, with a focus on AstraZeneca’s mature brands which are used by patients around the world.

The Global Business Services (GBS), which now houses Global Commercial Operations (GCO), was set up in Chennai in 2017 and has driven efficiency across content management, multichannel marketing and analytics and reporting. GCO Global supports E2E commercial content management to markets - from creation, production, review, process, publishing and reporting. GCO helps multiple markets to avoid duplication of content leading to faster launches and cost savings.

Business area of the company

The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory.

Core Therapy Areas

  • Cardiovascular
  • Oncology
  • Respiratory

Milestones and achievements

  • 1979: Astra IDL formation.
  • 1982: Astra factory foundation.
  • 1992: Launch of Cerviprime, Plendil, Ramace, Rhinocort and Imdur.
  • 2001: Merger of Astra & Zeneca in 1999 globally, formed ‘AstraZeneca’ name in India in 2001.
  • 2015: Launch of Forxiga.
  • 2017: Launch of Tagrisso.
  • 2018: Launch of Xigduo XR.
  • 2018: Launch of first Metabolic Centre of Excellence in India.
  • 2019: Launch of Lynparza.
  • 2020: AstraZeneca India launches Qtern.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.